



<b>Paper No. SET/70/22</b>	
	<b>Tick One ✓</b>
For discussion	✓
For approval	
For information/noting	

**Date of Trust Board Meeting:** 28 September 2022  
**Confidential or Public Agenda:** Public  
**Agenda item:** IHRD Update

**1.0 Introduction**

This paper provides an update from the IHRD Recommendations Implementation Oversight Group.

**2.0 Background Information**

In January 2018, Justice John O’Hara published the report on the Inquiry into Hyponatraemia Related Deaths (IHRD). In response, DoH established a programme to oversee implementation of its recommendations.

**3.0 Brief Summary of Key Points**

IHRD Programme Management representatives attended the local Oversight Group meeting of 12 August 2022. Proposals for advancing the Programme were presented. A Phase 1 would see 49 of the 120 actions considered implemented with the caveat that ‘further work to enhance a regional approach may be required’. The actions span Programme Workstreams but are mostly from the Paediatric Clinical Group, Clinical and Social Care Sub-Group and ALB Board Effectiveness.

Closure of recommendations will be accompanied by an evidenced assurance process with sign-off required from the Trust Chairman. The remaining actions would be taken forward in a Phase 2, comprised of a 2A and 2B. Phase 2A comprises 35 actions and will be taken forward by the IHRD Programme Management team and Phase 2B by the relevant Policy Lead within the Department of Health. Progress on these will reported regularly to a Programme Management Board. A co-production approach will be used with Phase 1 learning informing Phase 2.

Formal notifications will be issued following sign off for this approach from the Minister of Health and Permanent Secretary. It is anticipated that the formal closure of Phase 1 and the launch of Phase 2 will take place in October 2022. Trusts should expect increased engagement activity from the Programme as work towards the Duty of Candour Being Open Framework begins. This will include requests for meetings with the Trust Board and Chief Executive. Work will examine the support needs for individuals and organisations, and address the cultural challenges together with establishing linkages to the developing legal framework.

**4.0 Recommendation for Trust Board**

That Trust Board consider this tabled update.

**Lead Director:** Charlie Martyn  
**Designation:** Medical Director  
**Date:** 28 September 2022